Zhou F, Zhang Y, Zhang D
Department of Tropical Diseases, Faculty of Naval Medicine, Naval Medical University, Shanghai 200433, China.
Co-first authors.
Zhongguo Xue Xi Chong Bing Fang Zhi Za Zhi. 2024 Mar 29;36(2):201-206. doi: 10.16250/j.32.1374.2023102.
Tuberculosis (TB) remains one of the biggest infectious killers worldwide. Vaccine is the most satisfactory tool for prevention of TB; however, Bacillus Calmette-Guérin (BCG), the widely used vaccine in clinical for the prevention of TB, has limitations in protective effects. Development of novel TB vaccines is therefore of urgent need. Currently, there are 15 novel TB vaccine candidates in clinical trials, including live-attenuated vaccines, inactivated vaccines, subunit vaccines and viral-vectored vaccines, which open the door for the ultimate target of the End TB Strategy. This review summarizes the latest advances in the development of TB vaccines in global clinical trials, so as to provide insights into TB control.
结核病（TB）仍然是全球最大的传染性杀手之一。疫苗是预防结核病最理想的工具；然而，卡介苗（BCG）作为临床上广泛用于预防结核病的疫苗，在保护效果方面存在局限性。因此，迫切需要开发新型结核病疫苗。目前，有15种新型结核病候选疫苗正在进行临床试验，包括减毒活疫苗、灭活疫苗、亚单位疫苗和病毒载体疫苗，这为终结结核病战略的最终目标打开了大门。本综述总结了全球临床试验中结核病疫苗开发的最新进展，以期为结核病防控提供思路。
